{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:55:20Z","timestamp":1759964120677,"version":"3.32.0"},"reference-count":51,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3574,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2005.00737.x","type":"journal-article","created":{"date-parts":[[2005,11,18]],"date-time":"2005-11-18T23:38:25Z","timestamp":1132357105000},"page":"1464-1471","source":"Crossref","is-referenced-by-count":13,"title":["Ezetimibe\/simvastatin (INEGY\u2122) in the treatment of hyperlipidaemia"],"prefix":"10.1155","volume":"59","author":[{"given":"J. J. P.","family":"Kastelein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. R.","family":"Sankatsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,11,18]]},"reference":[{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archinte.160.4.459","article-title":"The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals","volume":"160","author":"Pearson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/euhj.2001.2610","article-title":"Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal result from EUROASPIRE II Euro Heart Survey Programme","volume":"22","author":"Euroaspire II Study Group.","year":"2001","journal-title":"Eur Heart J"},{"issue":"Suppl. 3","key":"10.1111\/j.1368-5031.2005.00737.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422003-00002","article-title":"Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study","volume":"22","author":"Garc\u00eda Ruiz","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1185\/030079904125004114","article-title":"Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study","volume":"20","author":"Goettsch","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/204748730501200106","article-title":"Real-world effectiveness of lipid-lowering therapy in male and female outpatients with CHD: relation to pre-treatment LDL-cholesterol, pre-treatment CHD risk, and other factors","volume":"1","author":"Krobot","year":"2005","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2004.02.059","article-title":"Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals","volume":"93","author":"Feldman","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4065\/79.5.620","article-title":"Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial","volume":"79","author":"Goldberg","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagn\u00e9","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB13|cit13","first-page":"1383","article-title":"Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"The Scandinavian Simvastatin Survival Study Group.","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group.","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-3565(24)36992-7","article-title":"In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461","volume":"283","author":"Van Heek","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.bjp.0704260","article-title":"Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function","volume":"134","author":"Van Heek","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0149-2918(01)80102-8","article-title":"Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies","volume":"23","author":"Bays","year":"2001","journal-title":"Clin Ther"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1053\/meta.2001.26737","article-title":"The synergistic hypercholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs","volume":"50","author":"Davis","year":"2001","journal-title":"Metabolism"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2125.2002.01633.x","article-title":"Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin","volume":"54","author":"Kosoglou","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","article-title":"A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe\/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia","volume":"26","author":"Bays","year":"2004","journal-title":"Clin Ther"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB23|cit23","unstructured":"Gaudiani L Lewin A Meneghini L et al. 2004"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB24|cit24","unstructured":"McKenney J Insull W Lewin A et al. 2004"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.amjcard.2003.08.048","article-title":"Effect of coadministration of ezetimibe and simvastatin on high-sensitivity c-reactive protein","volume":"92","author":"Sager","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-140-8-200404200-00034","article-title":"Ezetimibe and statin associated myopathy","volume":"140","author":"Fux","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults.","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin","volume":"148","author":"Stein","year":"2004","journal-title":"Am Heart J"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1368-5031.2004.00278.x","article-title":"Long-term safety and tolerability profile of ezetimibe and atorvastatin co-administration therapy in patients with primary hypercholesterolemia","volume":"58","author":"Ballantyne","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0195-668X(02)00803-5","article-title":"Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"24","author":"Melani","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0002-9149(02)03236-8","article-title":"Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia","volume":"91","author":"Kerzner","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1185\/030079904125004213","article-title":"Pharmacodynamic interaction between ezetimibe and rosuvastatin","volume":"20","author":"Kosoglou","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2004.00289.x","article-title":"Efficacy and safety of ezetimibe coadministered with statins: randomized, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia","volume":"58","author":"Davidson","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1742-1241.2003.tb10508.x","article-title":"Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies","volume":"57","author":"Knopp","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1399-0004.2004.00388.x","article-title":"Compund heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe","volume":"67","author":"Wang","year":"2005","journal-title":"Clin Genet"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079905X28872","article-title":"Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias","volume":"21","author":"Wierzbicki","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1567-5688(01)00020-4","article-title":"The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment","volume":"2","author":"Stein","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes","volume":"292","author":"De Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50-70 mg\/dl","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for management of hypertension: report of the fourth Working Party of the British Hypertension Society, 2004-BHS IV","volume":"18","author":"Williams","year":"2004","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(04)16936-5","article-title":"Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)","volume":"364","author":"Strandberg","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/hq1201.100260","article-title":"Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice","volume":"21","author":"Davis","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","volume":"84","author":"Baigent","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB50|cit50","unstructured":"Kastelein JP Sager PT De Groot E Veltri EP. 2003"},{"key":"10.1111\/j.1368-5031.2005.00737.x-BIB51|cit51","unstructured":"Rosseb\u00f8 A Pedersen T Skjaerpe T et al. for the SEAS Steering Committee. 2003"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2005.00737.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2005.00737.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T18:47:27Z","timestamp":1736102847000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2005.00737.x"}},"subtitle":["Treatment of Hyperlipidaemia"],"short-title":[],"issued":{"date-parts":[[2005,11,18]]},"references-count":51,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00737.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"type":"print","value":"1368-5031"}],"subject":[],"published":{"date-parts":[[2005,11,18]]}}}